← All companies
JOHNSON & JOHNSON
JNJ - CIK 0000200406
Market cap$574.10 B
Rank#20
SEC filings984
JOHNSON & JOHNSON trades as JNJ and has a market capitalization of $574.10 B, making it the #20 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $94.19B, up 6.0% from the prior year and net income of $26.80B. This page tracks JOHNSON & JOHNSON through 984 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$94.19BFY 2025
Net income (latest FY)$26.80BFY 2025
Operating cash flow (latest FY)$24.53BFY 2025
Total assets (latest FY)$199.21BFY 2025
Gross margin67.9%latest FY
Net margin28.5%latest FY
Financial performance
Over the last 8 fiscal years JOHNSON & JOHNSON's revenue grew from $71.89B to $94.19B, a compound annual growth rate of 3.4%. Net profit margin expanded from 23.0% to 28.5% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $574.10 B
- Share price (derived)market cap / shares outstanding
- $238.49
- P/E ratio (trailing FY)
- 21.4
- EPS (diluted)FY 2025
- $11.03
- Shares outstandingas of 2026-04-17
- 2.41B
- Total equityas of 2026-03-29
- $81.19B
- Return on equity
- 33.0%
- Long-term debtas of 2026-03-29
- $37.53B
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Institutional holdings | 13F-HR | 2026-05-13 |
| Insider trade | 4 | 2026-05-04 |
| SCHEDULE 13G | - | 2026-05-01 |
| Major company event | 8-K | 2026-04-28 |
| Insider trade | 4 | 2026-04-27 |
| Insider trade | 4 | 2026-04-27 |
| Insider trade | 4 | 2026-04-27 |
| Insider trade | 4 | 2026-04-27 |
Recent press releases
- 2024 Health for Humanity Report2026-05-14
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
- Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter2026-05-12
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
- Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP2026-05-11
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
- Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference2026-05-11
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission2026-05-07
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
Similar companies
The largest companies sharing JOHNSON & JOHNSON's SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is JOHNSON & JOHNSON's market cap?
JOHNSON & JOHNSON (JNJ) has a market capitalization of $574.10 B as of 2026-06-11, ranking #20 among US-listed companies.
How much revenue does JOHNSON & JOHNSON make?
JOHNSON & JOHNSON reported revenue of $94.19B for fiscal year 2025, an increase of 6.0% year over year.
Is JOHNSON & JOHNSON profitable?
Yes. JOHNSON & JOHNSON reported net income of $26.80B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.